Digestive Diseases and Sciences

, Volume 54, Issue 8, pp 1783–1788 | Cite as

The Effectiveness of the Treatment of Octreotide on Chylous Ascites After Liver Cirrhosis

  • Dong Xun Zhou
  • Hua Bang Zhou
  • Qing Wang
  • Shan Shan Zou
  • Hao Wang
  • He Ping Hu
Original Article


Octreotide is a crucial drug used for treating patients with chylous ascites; however, there have been few reports related to octreotide that are being used in cirrhotic patients. Thus, this thesis is designed to determine the effects of octreotide on patients with chylous ascites after liver cirrhosis. Eight patients were diagnosed with chylous ascites, on the basis of laboratory findings on ascites samples, between January 2003 and May 2008. Octreotide was given to the six patients, while the remaining two were treated as a control. All patients had persistent peritonea drainage with the quantity and quality of the drainage fluid observed once every other day. All the necessary care was individually given to the patients during the therapy. All patients properly received combined therapy including a low-fat and low-sodium diet, and diuretic and peritoneal drainage. The volume of the peritoneal drainage was reduced to zero in one of the six patients who received octreotide therapy, while the other five had the drainage volumes decreased from 2,000 to 50 ml with a clear appearance and negative qualitative analysis of chyle. For those two patients who did not receive octreotide therapy, the conditions of peritoneal drainage seldom changed both from the qualitative and quantitative aspects. In conclusion, Octreotide, along with combined therapy, can rapidly relieve portal hypertension and reduce triglyceride levels in ascites. It appears to be an effective therapy available for the treatment of chylous ascites caused by liver cirrhosis.


Octreotide Chylous ascites Liver cirrhosis Portal hypertension 


  1. 1.
    Losanoff JE, Richman BW, Jones JW. Chylous ascites. Am J Gastroenterol. 2003;98(1):219–220. doi: 10.1111/j.1572-0241.2003.07203.x.PubMedCrossRefGoogle Scholar
  2. 2.
    Mincher L, Evans J, Jenner MW, et al. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol). 2005;17(2):118–121. doi: 10.1016/j.clon.2004.06.016.Google Scholar
  3. 3.
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2001;120(3):726–748. doi: 10.1053/gast.2001.22580.PubMedCrossRefGoogle Scholar
  4. 4.
    Gómez Soto FM, Marcos Sánchez F, Franco Moreno AI, et al. Chylous ascites chylosus as a manifestation of hepatocarcinoma. Gastroenterol Hepatol. 2003;26(4):276–277. doi: 10.1157/13045206.PubMedCrossRefGoogle Scholar
  5. 5.
    Castellote J, Porta F. Chylous ascites secondary to liver cirrhosis. Rev Esp Enferm Dig. 1994;86(6):912–914.PubMedGoogle Scholar
  6. 6.
    Bhatia C, Pratap U, Slavik Z. Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum. Arch Dis Child. 2001;85(3):234–235. doi: 10.1136/adc.85.3.234.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheung CK, Khwaja A. Chylous ascites: an unusual complication of peritoneal dialysis. A case report and literature review. Perit Dial Int. 2008;28(3):229–231.PubMedGoogle Scholar
  8. 8.
    Proveoza JM, Banoon BR. Chyloperitoneum associated with sarcoidoses. Am J Gastroenterol. 1993;88(9):1462–1463.Google Scholar
  9. 9.
    Rovira E, Moles JR, Hinojosa J, Primo J, Gonzalvo F, Albert A. Dysfunction of a TIPS-transjugular intrahepatic porto-systemic shunt and chylous ascites. Rev Esp Enferm Dig. 1997;89:475.PubMedGoogle Scholar
  10. 10.
    Ehrenpreis ED, Boiskin I, Schaefer K. Chylous ascites in a patient with mesenteric panniculits. J Clin Gastroenterol. 2008;42(3):327–328.PubMedGoogle Scholar
  11. 11.
    Romero S, Martín C, Hernandez L, et al. Chylothorax in cirrhosis of the liver: analysis of its frequency and clinical characteristics. Chest. 1998;114(1):154–159. doi: 10.1378/chest.114.1.154.PubMedCrossRefGoogle Scholar
  12. 12.
    Mishra R, Kumar S. Octreotide in congenital chylous ascites an avoid requirement of total parenteral nutrition. Indian J Gastroenterol. 2007;26(6):299–300.PubMedGoogle Scholar
  13. 13.
    Nakamura T, Kudoh K, Takebe K, et al. Octreotide decreases biliary and pancreatic exocrine function and induces steatorrhea in healthy subjects. Intern Med. 1994;33(10):593–596. doi: 10.2169/internalmedicine.33.593.PubMedCrossRefGoogle Scholar
  14. 14.
    Collard JM, Laterre PF, Boemer F, Reynaert M, Ponlot R. Conservative treatment of postsurgical lymphatic leaks with somatostatin-14. Chest. 2000;117(3):902–905. doi: 10.1378/chest.117.3.902.PubMedCrossRefGoogle Scholar
  15. 15.
    Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology. 1992;103(4):1207–1214.PubMedGoogle Scholar
  16. 16.
    Ferrandière M, Hazouard E, Guicheteau V, Gouchet A, et al. Chylous ascites following radical nephrectomy: efficiency of octreotide as treatment of a ruptured thoracic duct. Intensive Care Med. 2000;26(4):484–485. doi: 10.1007/s001340051190.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee PH, Lin CL, Lai PC, Yang CW. Octreotide therapy for chylous ascites in a chronic dialysis patient. Nephrology (Carlton). 2005;10(4):344–347. doi: 10.1111/j.1440-1797.2005.00427.x.CrossRefGoogle Scholar
  18. 18.
    Leong RW, House AK, Jeffrey GP. Chylous ascites caused by portal vein thrombosis treated with octreotide. J Gastroenterol Hepatol. 2003;18(10):1211–1213. doi: 10.1046/j.1440-1746.2003.02850.x.PubMedCrossRefGoogle Scholar
  19. 19.
    Huang Q, Jiang ZW, Jiang J, et al. Chylous ascites: treated with total parenteral nutrition and somatostatin. World J Gastroenterol. 2004;10(17):2588.PubMedGoogle Scholar
  20. 20.
    Shapiro AM, Brain VG, Sigalet DL. Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total nutrition. Transplantation. 1996;61:1410–1411. doi: 10.1097/00007890-199605150-00023.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Dong Xun Zhou
    • 1
  • Hua Bang Zhou
    • 1
  • Qing Wang
    • 1
  • Shan Shan Zou
    • 1
  • Hao Wang
    • 1
  • He Ping Hu
    • 1
  1. 1.Department of Comprehensive Treatment II, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations